Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dasatinib + bevacizumab + paclitaxel + methylnaltrexone
- Development stage
- Phase 1
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is an investigational combination therapy evaluated in a Phase I trial (NCT01015222) led by the M.D. Anderson Cancer Center. The regimen consists of metronomic (low-dose, frequent) paclitaxel, dasatinib (a BCR-ABL and SRC family tyrosine kinase inhibitor), and bevacizumab (a VEGF-targeting monoclonal antibody), with or without the addition of methylnaltrexone. The study targeted patients with advanced or metastatic malignancies refractory to standard treatments. The rationale behind the combination is to leverage the anti-angiogenic effects of metronomic chemotherapy and bevacizumab alongside the SRC inhibition provided by dasatinib to overcome resistance and inhibit tumor growth and metastasis. Methylnaltrexone was included in specific cohorts to evaluate its potential role in blocking opioid-receptor-mediated signaling that may contribute to tumor progression and angiogenesis.
- Other names
- Metronomic paclitaxel combination therapyDasatinib + Bevacizumab + Paclitaxel +/- Methylnaltrexone
02
Targets
ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)VEGFA (Vascular endothelial growth factor A)MOR (Mu opioid receptor)SRC (Proto-oncogene tyrosine-protein kinase Src)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on dasatinib + bevacizumab + paclitaxel + methylnaltrexone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dasatinib + bevacizumab + paclitaxel + methylnaltrexone.